Even with this partial rebound, Lilly's share price remains roughly 13% below the peak set in late August. Some investors ...

Driven by new product successes and strategic investments, Eli Lilly and Co (LLY) reports a 42% revenue increase, setting a ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Here's why Eli Lilly is a no-brainer stock to buy on the ... incurred in Q3 that were primarily related to its acquisition of Morphic Holding. Without this acquisition, Lilly almost certainly ...

Eli Lilly (NYSE: LLY) stock tanked after the company ... expenses related to the recent acquisition of Morphic Holding. The expectations Lilly missed weren't nearly as significant as the still ...

The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.

Eli Lilly’s (NYSE: LLY) market isn’t out of the weeds yet ... grew by 17% and will accelerate in Q4 due to the latest ...

Adding to the quarterly woes, a $2.8 billion charge related to the acquisition of Morphic Holding dented results further. Analysts responded to the mixed earnings by revising their outlook on Eli ...